AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactive the company has successfully dosed the first participants in its AD-214 Phase I extension study, marking the next milestone in the drug's development. AD-214 is being developed to target fibrotic diseases. AdAlta is on track to achieve interim results from the study before the end of 2023, providing a glimpse into the drug's potential. The final assessment visits are expected to be completed, and full results are anticipated to be available in the first quarter of 2024.
“We extend our gratitude to the volunteers who are participating in this extension study,” Oldham said.
“Their involvement is essential in advancing a potential new therapy for sufferers of debilitating and incurable idiopathic pulmonary fibrosis and other fibrotic diseases.”
AdAlta will be holding an online briefing discussing progress of the AD-214 Phase 1 extension study on Thursday 10 August at 10:30am (AEDT).
To participate in the live webcast, shareholders, investors and interested parties are invited to click on the link below to register:
AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patientâs immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patientâs immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.